Nanexa: Focus on dual GLP-1 opportunities and the partner projects - Emergers

Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much new in Nanexa’s full year report. Following the streamlining of its activities, stemming from the outcome of the rights issue in December 2023, Nanexa now focuses on the projects most likely to generate near-term revenue and thus reduce the need for further external financing. We now look forward to the start of Phase I with NEX-22 in H1’24, as well as the outcome of the partner project with Novo Nordisk and other advanced evaluation projects, including the recent agreement for monoclonal antibodies for a Big Pharma company. All in all, we continue to find support for a fair value of SEK 2.6-9.9 per share.

Länk till analysen i sin helhet: https://www.emergers.se/nanexa_u24/